publication date: Jun. 9, 2017
Angela Hartley Brodie, pioneer in the development of breast cancer treatment, dies at 82
Source: University of Maryland Greenebaum Comprehensive Cancer Center
Angela Hartley Brodie, professor emeritus in the Department of Pharmacology at the University of Maryland School of Medicine and a scientist whose groundbreaking research is considered among the greatest advances in treating breast cancer, died of complications from Parkinson’s disease at her home in Fulton, MD. She was 82.
Brodie pioneered the development of aromatase inhibitor. Her work developing aromatase inhibitors was a paradigm-shifting effort that began in the 1970s and was designed to reduce the level of the estrogen in the body and thereby block the growth of cancer cells.
Aromatase is an enzyme that plays a key role in the biosynthesis of estrogen, which fuels the growth of cancer cells.
“Dr. Angela Brodie’s impact on the treatment of breast cancer has been unparalleled. It is because of her work that a disease that was once almost a certain death sentence, can now, for many, be successfully treated and managed,” said E. Albert Reece, vice president for Medical Affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor and Dean of the University of Maryland School of Medicine.
“She never gave up on her vision of finding a new treatment with fewer side effects, and many women around the world have benefitted from her perseverance.”
Brodie’s research spanned decades and built upon her initial discoveries to create more powerful and specific aromatase inhibitors.
“Dr. Brodie’s pioneering research is equal to the greatest advances in treating breast cancer in the last 150 years,” said Kevin Cullen, the Marlene and Stewart Greenebaum Distinguished Professor of Oncology at the … Continue reading Angela Hartley Brodie, pioneer in the development of breast cancer treatment, dies at 82
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.